×

Biotech and Pharmaceuticals Pharmaceuticals

  • The drugmaker's shares were up 2.37 percent at 4,554 pence on the London Stock Exchange, while its U.S.-listed shares were up 1.70 percent at $29.25 in premarket trading on Friday. Lynparza, which won U.S. approval for ovarian cancer in 2014 and generated 2016 sales of $218 million, is one of the drugs that the drugmaker hopes will help achieve its target of more...

  • FRANKFURT, Feb 17- German generic drugs company Stada has received a new takeover approach which values it at 3.6 billion euros, raising the stakes in a three-way bidding war and pushing its shares to a new record. Two people familiar with the matter identified the new bidder on Friday as buyout group Bain Capital. The company said earlier this week that buyout...

  • Millennial couple together

    While the development of contraceptives aimed at men is gaining ground, interest from big pharma just isn't there, according to one expert.

  • *New offer values Stada at 3.6 bln eur. FRANKFURT, Feb 16- German generic drugs company Stada said on Thursday it had received its third takeover approach, and at 58 euros per share, the latest offer was two euros higher than rival suitor Cinven Partners' offer. Private equity firm Advent International was the second prospective bidder though a price has not been...

  • "The idea that perhaps Medicaid programs, which are struggling to pay for those programs, that they could have potentially received rebates is disturbing to me." Mylan has been criticized for listing EpiPen with Medicaid as a generic product even though it listed it with the Food and Drug Administration as a branded product. The classification led to Mylan's...

  • BERLIN, Feb 16- German generic drugs company Stada said on Thursday it had received another takeover approach, the third so far and at 58 euros per share, two euros up on rival suitor Cinven Partners' offer. The company said earlier this week that the private equity investment firm had offered 56 euros per share, but it has not disclosed the price proposed by the...

  • MILAN, Feb 16- The European Union is likely to select a new home for the bloc's London- based medicines regulator by June, according to the mayor of Milan, one of several cities vying to host the organisation after Brexit. Other countries vying to host the agency include Denmark, Sweden, Spain, France, Ireland and Poland. Sala was flanked at the briefing by Economy...

  • Martin Shkreli, former Chief Executive Officer of Turing Pharmaceuticals

    A fire alarm rang out moments before indicted former pharmaceutical executive Martin Shkreli was to speak at Harvard University.

  • Tepper's Appaloosa triples stake in Allergan

    CNBC's Leslie Picker reports on David Tepper's Allergan bet as he ups the stake by 250%. With CNBC's Meg Tirrell.

  • Stocks to Watch: February 15, 2017

    PepsiCo, Merck, and Apple stocks are making headlines this Wednesday morning before the opening bell.

  • President Donald Trump's vow to roll back government regulations at least 75 percent is causing anxiety for some pharmaceutical executives that a less robust Food and Drug Administration would make it harder to secure insurance coverage for pricey new medicines. The prospect of big change at the regulatory agency comes as drugmakers are under fire for...

  • LONDON, Feb 15- Treatment with two important cancer drugs is about to get much cheaper in Europe with a cut-price copy of Roche's blood cancer drug Rituxan likely to hit the market imminently followed by a rival to its breast cancer medicine Herceptin. Approval from the pan-European regulator, the European Medicines Agency, is pending and preparations are...

  • President Donald Trump's vow to roll back government regulations at least 75 percent is causing anxiety for some pharmaceutical executives that a less robust Food and Drug Administration would make it harder to secure insurance coverage for pricey new medicines. The prospect of big change at the regulatory agency comes as drugmakers are under fire for...

  • KENILWORTH, N.J.— Merck& Co. will stop its study of an experimental Alzheimer's drug in people with mild or moderate symptoms because interim results showed "virtually no chance" of any benefit. However, the drugmaker said Tuesday it will continue another study of the drug, verubecestat, in patients who don't yet show symptoms. While a few treatments temporarily...

  • CARLSBAD, Calif. _ Natural Alternatives International Inc. on Tuesday reported fiscal second-quarter profit of $2.5 million. Natural Alternatives shares have declined 3 percent since the beginning of the year. Keywords: Natural Alternatives, Earnings Report.

  • Davis: Innovation without access equates to a medicine on a shelf

    Chester Davis, Association for Accessible Medicines CEO weighs in on highly-priced generic drugs.

  • Generic drug price showdown

    CNBC's Meg Tirrell reports the latest on how the fight over drug prices has sparked a civil war in the pharmaceutical industry, with big branded companies in one corner and the generics in the other.

  • MUMBAI, Feb 14- Sun Pharmaceutical Industries, India's largest drugmaker, reported its first fall in quarterly profits in a year on Tuesday, as pricing issues and supply constraints affected sales in the United States, its largest market. Sun's U.S. business faces increasing uncertainty as it struggles to fix quality control problems found by regulators at its...

  • *Q3 U.S. sales up 4 pct, India sales up 5 pct. MUMBAI, Feb 14- Sun Pharmaceutical Industries, India's largest drugmaker, reported its first fall in quarterly profits in a year on Tuesday, due to slower sales in the United States, its largest market. The firm's business in the United States has been pressured over the past year due to increasing competition and regulatory...

  • ZURICH, Feb 14- Swiss drugmaker Actelion's 2016 core net income rose 27 percent on accelerating sales of its newer medicines to treat deadly pulmonary arterial hypertension, it said on Tuesday. Core net income rose to 881 million Swiss francs from 693 million francs in the previous year, the company said in a statement. Europe's biggest biotech sold itself for...